Repeated administration of piribedil induces less dyskinesia than L‐dopa in MPTP‐treated common marmosets: A behavioural and biochemical investigation
Identifieur interne : 000468 ( France/Analysis ); précédent : 000467; suivant : 000469Repeated administration of piribedil induces less dyskinesia than L‐dopa in MPTP‐treated common marmosets: A behavioural and biochemical investigation
Auteurs : Lance A. Smith [Royaume-Uni] ; Banu C. Tel [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Rogelio Braceras [Royaume-Uni] ; Céline Bonhomme [France] ; Claire Chezaubernard [France] ; Susanna Del Signore [France] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-09.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Singe.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects), Agonist, Animal, Animals, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antiparkinson agent, Arousal (drug effects), Callithrix, Caudate Nucleus (metabolism), Chemotherapy, Comparative study, Corpus Striatum (metabolism), Culture Techniques, Dopamine receptor, Drug Administration Schedule, Dyskinesia, Dyskinesia, Drug-Induced (etiology), Dyskinesias (diagnosis), Dyskinesias (drug therapy), Dyskinesias (metabolism), Experimental disease, Female, In Situ Hybridization, Levodopa, Levodopa (adverse effects), Locomotion (drug effects), MPTP‐treated primates, Male, Monkey, Parkinson disease, Parkinson's disease, Piribedil, Piribedil (administration & dosage), Piribedil (adverse effects), Piribedil (therapeutic use), RNA, Messenger (metabolism), Severity of Illness Index, Time Factors, Treatment, dyskinesia, locomotor activity, piribedil, vigilance.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Piribedil.
- chemical , adverse effects : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Antiparkinson Agents, Levodopa, Piribedil.
- chemical , metabolism : RNA, Messenger.
- chemical , therapeutic use : Antiparkinson Agents, Piribedil.
- diagnosis : Dyskinesias.
- drug effects : Arousal, Locomotion.
- drug therapy : Dyskinesias.
- etiology : Dyskinesia, Drug-Induced.
- metabolism : Caudate Nucleus, Corpus Striatum, Dyskinesias.
- Animals, Callithrix, Culture Techniques, Drug Administration Schedule, Female, In Situ Hybridization, Male, Severity of Illness Index, Time Factors.
Abstract
Piribedil ([1‐(3,4‐methylenedioxybenzyl)‐4‐(2‐pyrimidinyl)piperazine]; S 4200) is a dopamine agonist with equal affinity for D2/D3 dopamine receptors effective in treating Parkinson's disease as monotherapy or as an adjunct to levodopa (L‐dopa). However, its ability to prime basal ganglia for the appearance of dyskinesia is unknown. We now report on the ability of repeated administration of piribedil to induce dyskinesia in drug naïve 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) ‐lesioned common marmosets compared with L‐dopa and its actions on the direct and indirect striatal outflow pathways. Administration of piribedil (4.0–5.0 mg/kg orally) or L‐dopa (12.5 mg/kg orally plus carbidopa 12.5 mg/kg orally twice daily) produced equivalent increases in locomotor activity and reversal of motor deficits over a 28‐day study period. Administration of L‐dopa resulted in the progressive development of marked dyskinesia over the period of study. In contrast, administration of piribedil produced a significantly lower degree and intensity of dyskinesia. Surprisingly, piribedil caused an increase in vigilance and alertness compared to L‐dopa, which may relate to the recently discovered α2‐noradrenergic antagonist properties of piribedil. The behavioural differences between piribedil and L‐dopa are reflected in the biochemical changes associated with the direct striatal output pathway. Administration of L‐dopa or piribedil did not reverse the MPTP‐induced up‐regulation of preproenkephalin A mRNA in rostral or caudal areas of the putamen or caudate nucleus. In contrast, administration of either piribedil or L‐dopa reversed the downregulation of preprotachykinin mRNA induced by MPTP in rostral and caudal striatum. L‐dopa, but not Piribedil, reversed the decrease in preproenkephalin B mRNA produced by MPTP treatment. © 2002 Movement Disorder Society
Url:
DOI: 10.1002/mds.10200
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000000
- to stream Istex, to step Curation: 000000
- to stream Istex, to step Checkpoint: 002C01
- to stream PubMed, to step Corpus: 003964
- to stream PubMed, to step Curation: 003964
- to stream PubMed, to step Checkpoint: 003953
- to stream Ncbi, to step Merge: 000887
- to stream Ncbi, to step Curation: 000887
- to stream Ncbi, to step Checkpoint: 000887
- to stream Main, to step Merge: 006315
- to stream PascalFrancis, to step Corpus: 002609
- to stream PascalFrancis, to step Curation: 000712
- to stream PascalFrancis, to step Checkpoint: 002626
- to stream Main, to step Merge: 006665
- to stream Main, to step Curation: 004310
- to stream Main, to step Exploration: 004310
- to stream France, to step Extraction: 000468
Links to Exploration step
ISTEX:1534D5F3549EE119309F24C929035455C19C4CB7Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Repeated administration of piribedil induces less dyskinesia than L‐dopa in MPTP‐treated common marmosets: A behavioural and biochemical investigation</title><author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name></author><author><name sortKey="Tel, Banu C" sort="Tel, Banu C" uniqKey="Tel B" first="Banu C." last="Tel">Banu C. Tel</name></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name></author><author><name sortKey="Hansard, Matthew J" sort="Hansard, Matthew J" uniqKey="Hansard M" first="Matthew J." last="Hansard">Matthew J. Hansard</name></author><author><name sortKey="Braceras, Rogelio" sort="Braceras, Rogelio" uniqKey="Braceras R" first="Rogelio" last="Braceras">Rogelio Braceras</name></author><author><name sortKey="Bonhomme, Celine" sort="Bonhomme, Celine" uniqKey="Bonhomme C" first="Céline" last="Bonhomme">Céline Bonhomme</name></author><author><name sortKey="Chezaubernard, Claire" sort="Chezaubernard, Claire" uniqKey="Chezaubernard C" first="Claire" last="Chezaubernard">Claire Chezaubernard</name></author><author><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1534D5F3549EE119309F24C929035455C19C4CB7</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10200</idno><idno type="url">https://api.istex.fr/document/1534D5F3549EE119309F24C929035455C19C4CB7/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000000</idno><idno type="wicri:Area/Istex/Curation">000000</idno><idno type="wicri:Area/Istex/Checkpoint">002C01</idno><idno type="wicri:doubleKey">0885-3185:2002:Smith L:repeated:administration:of</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:12360537</idno><idno type="wicri:Area/PubMed/Corpus">003964</idno><idno type="wicri:Area/PubMed/Curation">003964</idno><idno type="wicri:Area/PubMed/Checkpoint">003953</idno><idno type="wicri:Area/Ncbi/Merge">000887</idno><idno type="wicri:Area/Ncbi/Curation">000887</idno><idno type="wicri:Area/Ncbi/Checkpoint">000887</idno><idno type="wicri:doubleKey">0885-3185:2002:Smith L:repeated:administration:of</idno><idno type="wicri:Area/Main/Merge">006315</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:02-0584903</idno><idno type="wicri:Area/PascalFrancis/Corpus">002609</idno><idno type="wicri:Area/PascalFrancis/Curation">000712</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002626</idno><idno type="wicri:doubleKey">0885-3185:2002:Smith L:repeated:administration:of</idno><idno type="wicri:Area/Main/Merge">006665</idno><idno type="wicri:Area/Main/Curation">004310</idno><idno type="wicri:Area/Main/Exploration">004310</idno><idno type="wicri:Area/France/Extraction">000468</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Repeated administration of piribedil induces less dyskinesia than L‐dopa in MPTP‐treated common marmosets: A behavioural and biochemical investigation</title><author><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Tel, Banu C" sort="Tel, Banu C" uniqKey="Tel B" first="Banu C." last="Tel">Banu C. Tel</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Hansard, Matthew J" sort="Hansard, Matthew J" uniqKey="Hansard M" first="Matthew J." last="Hansard">Matthew J. Hansard</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Braceras, Rogelio" sort="Braceras, Rogelio" uniqKey="Braceras R" first="Rogelio" last="Braceras">Rogelio Braceras</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Bonhomme, Celine" sort="Bonhomme, Celine" uniqKey="Bonhomme C" first="Céline" last="Bonhomme">Céline Bonhomme</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherches Internationales Servier, Direction de la Recherche et du Développement, Courbevoie</wicri:regionArea><wicri:noRegion>Courbevoie</wicri:noRegion><wicri:noRegion>Courbevoie</wicri:noRegion></affiliation></author><author><name sortKey="Chezaubernard, Claire" sort="Chezaubernard, Claire" uniqKey="Chezaubernard C" first="Claire" last="Chezaubernard">Claire Chezaubernard</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherches Internationales Servier, Direction de la Recherche et du Développement, Courbevoie</wicri:regionArea><wicri:noRegion>Courbevoie</wicri:noRegion><wicri:noRegion>Courbevoie</wicri:noRegion></affiliation></author><author><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherches Internationales Servier, Direction de la Recherche et du Développement, Courbevoie</wicri:regionArea><wicri:noRegion>Courbevoie</wicri:noRegion><wicri:noRegion>Courbevoie</wicri:noRegion></affiliation></author><author><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Diseases Research Centre, Guy's, King's and St. Thomas' School of Biomedical Sciences, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-09">2002-09</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="887">887</biblScope><biblScope unit="page" to="901">901</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1534D5F3549EE119309F24C929035455C19C4CB7</idno><idno type="DOI">10.1002/mds.10200</idno><idno type="ArticleID">MDS10200</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects)</term><term>Agonist</term><term>Animal</term><term>Animals</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antiparkinson agent</term><term>Arousal (drug effects)</term><term>Callithrix</term><term>Caudate Nucleus (metabolism)</term><term>Chemotherapy</term><term>Comparative study</term><term>Corpus Striatum (metabolism)</term><term>Culture Techniques</term><term>Dopamine receptor</term><term>Drug Administration Schedule</term><term>Dyskinesia</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Dyskinesias (diagnosis)</term><term>Dyskinesias (drug therapy)</term><term>Dyskinesias (metabolism)</term><term>Experimental disease</term><term>Female</term><term>In Situ Hybridization</term><term>Levodopa</term><term>Levodopa (adverse effects)</term><term>Locomotion (drug effects)</term><term>MPTP‐treated primates</term><term>Male</term><term>Monkey</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Piribedil</term><term>Piribedil (administration & dosage)</term><term>Piribedil (adverse effects)</term><term>Piribedil (therapeutic use)</term><term>RNA, Messenger (metabolism)</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment</term><term>dyskinesia</term><term>locomotor activity</term><term>piribedil</term><term>vigilance</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Piribedil</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Antiparkinson Agents</term><term>Levodopa</term><term>Piribedil</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>RNA, Messenger</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Piribedil</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Arousal</term><term>Locomotion</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Caudate Nucleus</term><term>Corpus Striatum</term><term>Dyskinesias</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Callithrix</term><term>Culture Techniques</term><term>Drug Administration Schedule</term><term>Female</term><term>In Situ Hybridization</term><term>Male</term><term>Severity of Illness Index</term><term>Time Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term><term>Animal</term><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Dyskinésie</term><term>Etude comparative</term><term>Lévodopa</term><term>Parkinson maladie</term><term>Pathologie expérimentale</term><term>Piribédil</term><term>Récepteur dopaminergique</term><term>Singe</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Piribedil ([1‐(3,4‐methylenedioxybenzyl)‐4‐(2‐pyrimidinyl)piperazine]; S 4200) is a dopamine agonist with equal affinity for D2/D3 dopamine receptors effective in treating Parkinson's disease as monotherapy or as an adjunct to levodopa (L‐dopa). However, its ability to prime basal ganglia for the appearance of dyskinesia is unknown. We now report on the ability of repeated administration of piribedil to induce dyskinesia in drug naïve 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) ‐lesioned common marmosets compared with L‐dopa and its actions on the direct and indirect striatal outflow pathways. Administration of piribedil (4.0–5.0 mg/kg orally) or L‐dopa (12.5 mg/kg orally plus carbidopa 12.5 mg/kg orally twice daily) produced equivalent increases in locomotor activity and reversal of motor deficits over a 28‐day study period. Administration of L‐dopa resulted in the progressive development of marked dyskinesia over the period of study. In contrast, administration of piribedil produced a significantly lower degree and intensity of dyskinesia. Surprisingly, piribedil caused an increase in vigilance and alertness compared to L‐dopa, which may relate to the recently discovered α2‐noradrenergic antagonist properties of piribedil. The behavioural differences between piribedil and L‐dopa are reflected in the biochemical changes associated with the direct striatal output pathway. Administration of L‐dopa or piribedil did not reverse the MPTP‐induced up‐regulation of preproenkephalin A mRNA in rostral or caudal areas of the putamen or caudate nucleus. In contrast, administration of either piribedil or L‐dopa reversed the downregulation of preprotachykinin mRNA induced by MPTP in rostral and caudal striatum. L‐dopa, but not Piribedil, reversed the decrease in preproenkephalin B mRNA produced by MPTP treatment. © 2002 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>France</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Smith, Lance A" sort="Smith, Lance A" uniqKey="Smith L" first="Lance A." last="Smith">Lance A. Smith</name></region><name sortKey="Braceras, Rogelio" sort="Braceras, Rogelio" uniqKey="Braceras R" first="Rogelio" last="Braceras">Rogelio Braceras</name><name sortKey="Hansard, Matthew J" sort="Hansard, Matthew J" uniqKey="Hansard M" first="Matthew J." last="Hansard">Matthew J. Hansard</name><name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name><name sortKey="Tel, Banu C" sort="Tel, Banu C" uniqKey="Tel B" first="Banu C." last="Tel">Banu C. Tel</name></country><country name="France"><noRegion><name sortKey="Bonhomme, Celine" sort="Bonhomme, Celine" uniqKey="Bonhomme C" first="Céline" last="Bonhomme">Céline Bonhomme</name></noRegion><name sortKey="Chezaubernard, Claire" sort="Chezaubernard, Claire" uniqKey="Chezaubernard C" first="Claire" last="Chezaubernard">Claire Chezaubernard</name><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000468 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000468 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:1534D5F3549EE119309F24C929035455C19C4CB7
|texte= Repeated administration of piribedil induces less dyskinesia than L‐dopa in MPTP‐treated common marmosets: A behavioural and biochemical investigation
}}
| This area was generated with Dilib version V0.6.23. |  |